Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

Halucenex to obtain just lately harvested first batch of psilocybe cubensis

VANCOUVER, British Columbia, May possibly 27, 2022 (Globe NEWSWIRE) — Optimi Well being Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian organization creating purely natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a provide agreement with Halucenex Lifetime Sciences Inc. (“Halucenex”), a wholly owned subsidiary of Creso Pharma of Australia (ASX: CPH). Halucenex is primarily based in Windsor, Nova Scotia and is a lifetime sciences enterprise concentrated on studying novel psychedelic compounds, building and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the clinical advantages of psychedelic drugs.

Also, Optimi needs to confirm that the supply agreement pertains to the entirety of the Company’s a short while ago harvested first batch of psilocybe cubensis mushrooms at its Princeton, British Columbia facility. The mushrooms will be provided to Halucenex in the variety of full, dried mushroom fruiting bodies.

“This initially provide settlement, coming so before long soon after our very first comprehensive cultivation cycle, is a powerful affirmation of our choice to pursue the advancement of purely natural, GMP psilocybin,” reported Monthly bill Ciprick, CEO of Optimi. “From this initial evidence-of-strategy batch, our cultivation team will carry on to scale our operations to satisfy the calls for of the sector, domestically and internationally with licensed entities and for unique individuals inside of Canada according to the conditions of the Distinctive Accessibility Software.”

Halucenex CEO, Invoice Fleming, suggests the settlement with Optimi is one particular equally organizations will advantage from.

“We’re extremely enthusiastic to be transferring forward on this offer arrangement with the team at Optimi Overall health,” said Fleming. “Among our leading priorities in the progress of a psychedelic-assisted psychotherapeutic design for situations these kinds of as stress and article-traumatic pressure ailment has been to secure a harmless, constant supply of GMP psilocybin.”

Authorized events fascinated in buying Optimi psilocybin and useful mushroom products ought to send an email to [email protected] the place a member of the revenue team will reply within 24 several hours.

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Well being Inc. is a homegrown, Canadian achievements tale making and providing natural, EU-GMP quality psilocybin and useful mushrooms that concentration on the wellness and wellness markets. Crafted with the goal to make scalable, natural mushroom formulations for transformational human ordeals, the Company’s objective is to be the variety a person trustworthy, compassionate supplier of harmless, purely natural GMP grade psilocybin across the planet. With a vertically integrated approach, Optimi intends to cultivate, extract, system and distribute high top quality practical and psychedelic mushroom solutions at its two services comprising a whole of 20,000 square ft in Princeton, British Columbia.

To completely look into the science of mushrooms, the Enterprise has gained a investigate exemption less than Wellness Canada Meals and Drug Rules (FDR) for the use of psilocybin and psilocin for scientific functions through its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license below Canada’s Narcotic Regulate Rules governing possession, distribution, sale, laboratory examination of and exploration and enhancement of psilocybin and psilocin formulations. Optimi is committed to qualified cultivation and quality generation matter to and in accordance with the conditions of all applicable legal guidelines and governing laws to make sure risk-free, excellent Canadian fungi generation.

Optimi was lately granted an modification to its Dealer’s Licence by Health Canada, allowing for the Firm to have a quota of up to 5000kg of dried psilocybin mushrooms – the equal of 10kg of psilocybin – and 100g of psilocin.

ABOUT HALUCENEX

Halucenex operates a 6000 sq ft health-related facility in Windsor, Nova Scotia with six remedy rooms and a safe laboratory committed to executing psychedelic-assisted psychotherapy and medical investigation. Halucenex intends to keep handle in excess of all elements of the solution progress approach – mycological study, extraction engineering, and synthetic formulation as perfectly as drug shipping and delivery systems, psychedelic-assisted psychotherapy and regulatory affairs.

Clinically, Halucenex is centered on investigating psilocybin, psilocybin-derivatives, and other psychedelic medicine for the uses of dealing with consumers suffering from PTSD and anxiety working with its detailed psilocybin-assisted psychotherapy treatment method design. Halucenex is dedicated to advancing the science all-around the use of psilocybin in psychedelic-assisted psychotherapy by:

For extra info or to request an interview, make sure you contact:

Michael Kydd
Media & Stakeholder Relations Advisor
Electronic mail: [email protected]
Phone: +1 (902) 880 6121

FORWARD‐LOOKING STATEMENTS

This news launch contains forward‐looking statements and forward‐looking information and facts in the meaning of Canadian securities laws (collectively, “forward‐looking statements”) that relate to Optimi’s present expectations and views of long run events. Any statements that convey, or contain conversations as to, expectations, beliefs, plans, objectives, assumptions or long term events or performance (normally, but not always, through the use of text or phrases these as “will probable end result,” “are expected to,” “expects,” “will keep on,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical information and may perhaps be forward‐looking statements and may possibly entail estimates, assumptions and uncertainties which could cause true success or results to differ materially from these expressed in this kind of forward‐looking statements. No assurance can be presented that these expectations will show to be appropriate and this sort of forward‐looking statements incorporated in this news launch must not be unduly relied upon. These statements converse only as of the day of this news launch. In specific and without limitation, this news launch incorporates forward‐ looking statements pertaining to actions proposed to be performed underneath the Company’s dealer’s license and connected organization related to psilocybin and psilocin and Optimi’s options, focus and targets.

Forward‐looking statements are based on a selection of assumptions and are issue to a range of dangers and uncertainties, numerous of which are beyond Optimi’s handle, which could lead to genuine benefits and events to vary materially from those people that are disclosed in or implied by this kind of forward‐looking statements. These hazards and uncertainties include things like, but are not minimal to, the impression and development of the COVID‐19 pandemic and other aspects set forth less than “Forward‐Looking Statements” and “Risk Factors” in the Company’s Yearly details Type dated January 12, 2022, and other steady disclosure filings out there under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, irrespective of whether as a end result of new details, long run gatherings or or else, apart from as may possibly be expected by regulation. New variables emerge from time to time, and it is not doable for Optimi to predict all of them or assess the affect of just about every these types of aspect or the extent to which any component, or blend of elements, could trigger results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this information launch are expressly qualified in their entirety by this cautionary statement.

Shots accompanying this announcement are readily available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b1df7352-0b4b-48e9-a3f1-950de89cd66a

https://www.globenewswire.com/NewsRoom/AttachmentNg/82589a86-5ae3-4399-b33e-5b4b9927bcb4